Biomedical Bonding’s (BMB) novel primer formulation has been granted a patent in China. The product is an enabling technology and part of the Bonevolent™ platform towards strong adhesion to metal implants, for use in resin-based fixation of bone fractures and dental restoration.
The recently granted patent is now valid in Europe and China, and will support BMB’s path toward commercialization.
Bonevolent technology capitalizes on a set of materials with a combination of strength, biocompatibility and adaptability. The composite resins are formulated with benign components that selectively react with each other in a physiological environment without affecting surrounding tissues.
The resins are solidified into strong composite materials on command in seconds with benign high-intensity visible light, similar to light-cured dental resins.
“We are happy to obtain one additional patent to further strengthen our Bonevolent IPR portfolio in key geographical regions. The primer patent family is unique and it protects all key components that collectively enable superior resins-based fixation of bones, metal or teeth. It is a critical component that will allow BMB to pursue its vision towards personalized treatment of both bone fractures fixation as well dental restorations,” says Founder and CEO, Prof. Michael Malkoch.
Biomedical Bonding's (BMB) novel primer formulation has been granted a patent in China. The product is an enabling technology and part of the Bonevolent™ platform towards strong adhesion to metal implants, for use in resin-based fixation of bone fractures and dental restoration.
The recently granted patent is now valid in Europe and China, and...
Biomedical Bonding’s (BMB) novel primer formulation has been granted a patent in China. The product is an enabling technology and part of the Bonevolent™ platform towards strong adhesion to metal implants, for use in resin-based fixation of bone fractures and dental restoration.
The recently granted patent is now valid in Europe and China, and will support BMB’s path toward commercialization.
Bonevolent technology capitalizes on a set of materials with a combination of strength, biocompatibility and adaptability. The composite resins are formulated with benign components that selectively react with each other in a physiological environment without affecting surrounding tissues.
The resins are solidified into strong composite materials on command in seconds with benign high-intensity visible light, similar to light-cured dental resins.
“We are happy to obtain one additional patent to further strengthen our Bonevolent IPR portfolio in key geographical regions. The primer patent family is unique and it protects all key components that collectively enable superior resins-based fixation of bones, metal or teeth. It is a critical component that will allow BMB to pursue its vision towards personalized treatment of both bone fractures fixation as well dental restorations,” says Founder and CEO, Prof. Michael Malkoch.
Copy to clipboard 
